Atigliflozin

DB21394InvestigationalSmall molecule

Atigliflozin is a small molecule drug. Atigliflozin is under investigation in clinical trial NCT00361738 (Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin... Atigliflozin has a monoisotopic molecular weight of 382.11 Da.

Mechanism: Pharmacologically active on Sodium/glucose cotransporter 2
Curator reviewed
Formula / weight: C₁₈H₂₂O₇S · 382.43 g/mol (avg)
Code names: AVE-2268

Resolves to

Compound

UNIIY0H7UPE4WJCAS647834-15-9ChEMBLCHEMBL5314949ChEBI759640PubChem10068465

Structure

InChIKeyBUXGTLNOWLNUKF-SOVHRIKKSA-NSMILESCOC1=CC=C(CC2=C(O[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=CS2)C=C1

Targets

P31639SLC5A2

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atigliflozin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account